U.S. Markets closed
  • S&P 500

    +13.89 (+0.36%)
  • Dow 30

    -36.98 (-0.12%)
  • Nasdaq

    +92.93 (+0.69%)
  • Russell 2000

    -5.49 (-0.25%)
  • Crude Oil

    +0.12 (+0.23%)
  • Gold

    -2.00 (-0.11%)
  • Silver

    -0.13 (-0.53%)

    0.0000 (-0.0000%)
  • 10-Yr Bond

    -0.0510 (-4.67%)
  • Vix

    +1.28 (+5.84%)

    -0.0009 (-0.0629%)

    +0.0110 (+0.0106%)

    +440.40 (+1.37%)
  • CMC Crypto 200

    -23.11 (-3.41%)
  • FTSE 100

    -56.22 (-0.84%)
  • Nikkei 225

    -123.25 (-0.43%)

Zacks Investment Ideas feature highlights: ProShares Ultra Health Care ETF, ProShares UltraShort Health Care ETF, Direxion Daily Healthcare Bull 3x Shares and Direxion Daily Healthcare Bear 3x Shares

For Immediate Release

Chicago, IL –June 28, 2012 – Today, Zacks Investment Ideas feature highlights Features: ProShares Ultra Health Care ETF (RXL), ProShares UltraShort Health Care ETF (RXD), Direxion Daily Healthcare Bull 3x Shares (CURE) and Direxion Daily Healthcare Bear 3x Shares (SICK).

Health Care ETFs & the Future of Obamacare

In summary, if the individual mandate is thrown out, it looks likely to spell bad news for the entire sector. That is because the mandate would add a ton of cheap-to-ensure people to the rolls of HMOs while it would drive up demand for devices, services and drugs, helping pretty much the entire industry.

If the bill is upheld in its entirety, a much more mixed outlook could be the result. With that being said, it will definitely be a big win for pharma, and to an extent healthcare providers and service companies as well. However, medical device makers look likely to be hurt by the ruling due to new taxes, while biotech could suffer from a similar issue as well (see Medical Device ETFs: A Better Way To Play Health Care?).

Lastly, if the entire bill is deemed unconstitutional, which at this point seems unlikely, it also could produce a mixed result. Broad health care is likely to stay about even, but investors could see a modest uptick for device makers and biotech, while pharma and the HMO market could be losers due to lower demand for their services.

Beyond these unleveraged choices, investors also have a few ways to play the decision with leverage. In total, there are four ETFs in this segment of the fund world, offering investors exposure to both bull and bear 2x strategies as well as both directions in 3x form as well:

ProShares Ultra Health Care ETF (RXL)/ ProShares UltraShort Health Care ETF (RXD)- These two products track, respectively, the 2x and -2x versions of the Dow Jones Health Care Index. This benchmark is heavily weighted towards big pharma, but it is still relatively spread out among its 122 securities.

Direxion Daily Healthcare Bull 3x Shares (CURE)/Direxion Daily Healthcare Bear 3x Shares (SICK)- These two products track, respectively, the 3x and -3x versions of the Health Care Select Sector Index. Much like their ProShares counterparts, these funds have a focus on big pharma, although they have a heavier level of concentration in their top securities, only holding 52 stocks in total (read Understanding Leveraged ETFs).

While the volumes on these products aren’t exactly the most robust in the ETF world-- suggesting relatively wide bid ask spreads-- they could see higher levels of activity leading up to and immediately following the in-focus decision. Given this, these products could be the way to play the situation, although investors should be prepared for a great deal of volatility and uncertainty no matter what health care stocks or ETFs they hold immediately following the pivotal Supreme Court ruling.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Len Zacks. The company continually processes stock reports issued by 3,000 analysts from 150 brokerage firms. It monitors more than 200,000 earnings estimates, looking for changes.

Then when changes are discovered, they’re applied to help assign more than 4,400 stocks into five Zacks Rank categories: #1 Strong Buy, #2 Buy, #3 Hold, #4 Sell, and #5 Strong Sell. This proprietary stock picking system; the Zacks Rank, continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter Profit from the Pros. In short, it’s your steady flow of profitable ideas GUARANTEED to be worth your time. Get your free subscription to Profit from the Pros at: http://at.zacks.com/?id=7298

Follow us on Twitter: http://twitter.com/ZacksResearch

Join us on Facebook: http://www.facebook.com/ZacksInvestmentResearch

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339



Read the analyst report on RXL

Read the analyst report on RXD

Read the analyst report on CURE

Read the analyst report on SICK

Zacks Investment Research

More From Zacks.com